These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 23632680)

  • 1. The cost of outpatient venous thromboembolism prophylaxis following lower limb injuries.
    Menakaya CU; Pennington N; Muthukumar N; Joel J; Ramirez Jimenez AJ; Shaw CJ; Mohsen A
    Bone Joint J; 2013 May; 95-B(5):673-7. PubMed ID: 23632680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery.
    Dranitsaris G; Stumpo C; Smith R; Bartle W
    Am J Cardiovasc Drugs; 2009; 9(1):45-58. PubMed ID: 19178131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients.
    Droege ME; Mueller EW; Besl KM; Lemmink JA; Kramer EA; Athota KP; Droege CA; Ernst NE; Keegan SP; Lutomski DM; Hanseman DJ; Robinson BR
    J Trauma Acute Care Surg; 2014 Feb; 76(2):450-6. PubMed ID: 24458050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of dalteparin versus unfractionated heparin as venous thromboembolism prophylaxis in malignant gynecologic surgery.
    Wade WE; Spruill WJ
    Am J Ther; 2008; 15(6):512-5. PubMed ID: 19127133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria.
    Dranitsaris G; Shane LG; Galanaud JP; Stemer G; Debourdeau P; Woodruff S
    Support Care Cancer; 2017 Jul; 25(7):2093-2102. PubMed ID: 28204995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient evaluation of outpatient venous thromboembolism prophylaxis service following lower limb injuries using a developed validated questionnaire.
    Menakaya CU; Khan AS; Nunn T; Pennington N; Ward M; Malhotra R; Muthukumar N; Mohsen A
    J Perioper Pract; 2015 Apr; 25(4):72-7. PubMed ID: 26012185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic Analysis Comparing Dalteparin to Vitamin K Antagonists to Prevent Recurrent Venous Thromboembolism in Patients With Cancer Having Renal Impairment.
    Dranitsaris G; Shane L; Burgers L; Woodruff S
    Clin Appl Thromb Hemost; 2016 Oct; 22(7):617-26. PubMed ID: 27436663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of dalteparin and enoxaparin in a hospital setting.
    Carson W; Schilling B; Simons WR; Parks C; Choe Y; Faria C; Powers A
    J Pharm Pract; 2012 Apr; 25(2):180-9. PubMed ID: 21987527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.
    Monreal M; Folkerts K; Diamantopoulos A; Imberti D; Brosa M
    Thromb Haemost; 2013 Nov; 110(5):987-94. PubMed ID: 23965805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venous Thromboembolism Prophylaxis in Outpatient Lower Limb Fractures and Injuries.
    Ajwani SH; Shaw A; Naiz O; Bhaskar D; Charalambous CP
    Ortop Traumatol Rehabil; 2016 May; 18(3):263-268. PubMed ID: 28157082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of venous thromboembolism in patients with cancer: role of dalteparin.
    Linkins LA
    Vasc Health Risk Manag; 2008; 4(2):279-87. PubMed ID: 18561503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dalteparin new treatment duration: new dosage. Is prolonged prophylaxis needed?
    Prescrire Int; 2000 Feb; 9(45):197-8. PubMed ID: 11503794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early venous thromboembolic event prophylaxis in traumatic brain injury with low-molecular-weight heparin: risks and benefits.
    Dudley RR; Aziz I; Bonnici A; Saluja RS; Lamoureux J; Kalmovitch B; Gursahaney A; Razek T; Maleki M; Marcoux J
    J Neurotrauma; 2010 Dec; 27(12):2165-72. PubMed ID: 20939698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient cost associated with filling a prescription for extended-duration venous thromboembolism (VTE) prophylaxis following surgery for gynecologic cancer.
    Cain K; Schmeler KM; Langley G; Max O; Ramirez PT; Levenback CF
    Gynecol Oncol; 2012 Oct; 127(1):18-21. PubMed ID: 22813886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
    Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
    Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial.
    Anderson DR; Dunbar MJ; Bohm ER; Belzile E; Kahn SR; Zukor D; Fisher W; Gofton W; Gross P; Pelet S; Crowther M; MacDonald S; Kim P; Pleasance S; Davis N; Andreou P; Wells P; Kovacs M; Rodger MA; Ramsay T; Carrier M; Vendittoli PA
    Ann Intern Med; 2013 Jun; 158(11):800-6. PubMed ID: 23732713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cost-effectiveness analysis of apixaban compared to dabigatran in the prevention of venous thromboembolism in patients subjected to total knee or hip replacement].
    Gómez-Cerezo JF; Gómez-Arrayás I; Suárez-Fernández C; Betegón-Nicolás L; de Salas-Cansado M; Rubio-Terrés C
    Rev Esp Cir Ortop Traumatol; 2012; 56(6):459-70. PubMed ID: 23594943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of extended preoperative thromboprophylaxis with dalteparin in patients with ovarian cancer qualified to surgical treatment.
    Krasiński Z; Szpurek D; Staniszewski R; Dzieciuchowicz L; Pawlaczyk K; Krasińska B; Wójcicka K; Urbanek T
    Int Angiol; 2014 Aug; 33(4):365-71. PubMed ID: 25056168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Venous thromboembolism prophylaxis in orthopaedics and traumatology].
    Kessler P
    Vnitr Lek; 2009 Mar; 55(3):204-10. PubMed ID: 19378847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A decision-tree model to estimate the impact on cost-effectiveness of a venous thromboembolism prophylaxis guideline.
    Ferrando A; Pagano E; Scaglione L; Petrinco M; Gregori D; Ciccone G
    Qual Saf Health Care; 2009 Aug; 18(4):309-13. PubMed ID: 19651937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.